

Sahar Keshvari

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6279658/publications.pdf>

Version: 2024-02-01

20
papers

284
citations

933447

10
h-index

996975

15
g-index

28
all docs

28
docs citations

28
times ranked

468
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic potential of macrophage colony-stimulating factor in chronic liver disease. <i>DMM Disease Models and Mechanisms</i> , 2022, 15, .	2.4	7
2	A kinase-dead <i>Csf1r</i> mutation associated with adult-onset leukoencephalopathy has a dominant inhibitory impact on CSF1R signalling. <i>Development (Cambridge)</i> , 2022, 149, .	2.5	9
3	Ex vivo glucocorticoid-induced secreted proteome approach for discovery of glucocorticoid-responsive proteins in human serum. <i>Proteomics - Clinical Applications</i> , 2021, 15, 2000078.	1.6	1
4	Analysis of homozygous and heterozygous <i>Csf1r</i> knockout in the rat as a model for understanding microglial function in brain development and the impacts of human CSF1R mutations. <i>Neurobiology of Disease</i> , 2021, 151, 105268.	4.4	29
5	The Mononuclear Phagocyte System of the Rat. <i>Journal of Immunology</i> , 2021, 206, 2251-2263.	0.8	15
6	CSF1R-dependent macrophages control postnatal somatic growth and organ maturation. <i>PLoS Genetics</i> , 2021, 17, e1009605.	3.5	44
7	Pre-Diabetes Increases Tuberculosis Disease Severity, While High Body Fat Without Impaired Glucose Tolerance Is Protective. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 691823.	3.9	8
8	Analysis of the impact of CSF-1 administration in adult rats using a novel <i>Csf1r</i> -mApple reporter gene. <i>Journal of Leukocyte Biology</i> , 2020, 107, 221-235.	3.3	35
9	SAT-LB136 A Proteomic Approach to Identify Circulating Glucocorticoid Responsive Proteins in Humans. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
10	The effect of glucocorticoids on Thrombospondin β 1, Osteocalcin and the Thrombospondin β 1:Osteocalcin ratio in humans. <i>Clinical Endocrinology</i> , 2019, 91, 728-736.	2.4	3
11	Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins. <i>Experimental Biology and Medicine</i> , 2018, 243, 166-183.	2.4	18
12	Perinatal exposure to high dietary advanced glycation end products in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction. <i>Islets</i> , 2018, 10, 10-24.	1.8	23
13	Muscle-specific overexpression of AdipoR1 or AdipoR2 gives rise to common and discrete local effects whilst AdipoR2 promotes additional systemic effects. <i>Scientific Reports</i> , 2017, 7, 41792.	3.3	13
14	Effects of Delayed Sample Processing on Determination of Total and High Molecular Weight (HMW) Adiponectin in Serum and Plasma: A Pilot Study. <i>International Journal of Chemistry</i> , 2016, 8, 19.	0.3	0
15	Identification of carboxypeptidase X (CPX) β 1 as a positive regulator of adipogenesis. <i>FASEB Journal</i> , 2016, 30, 2528-2540.	0.5	16
16	Development of an enzyme-linked immunosorbent assay for thrombospondin-1 and comparison of human plasma and serum concentrations. <i>Annals of Clinical Biochemistry</i> , 2016, 53, 606-610.	1.6	11
17	Thrombospondin-1 is a glucocorticoid responsive protein in humans. <i>European Journal of Endocrinology</i> , 2016, 174, 193-201.	3.7	8
18	Characterisation of the adiponectin receptors: Differential cell-surface expression and temporal signalling profiles of AdipoR1 and AdipoR2 are regulated by the non-conserved N-terminal trunks. <i>Molecular and Cellular Endocrinology</i> , 2015, 409, 121-129.	3.2	12

#	ARTICLE	IF	CITATIONS
19	Induction of heme-oxygenase-1 (HO-1) does not enhance adiponectin production in human adipocytes: Evidence against a direct HO-1 → Adiponectin axis. <i>Molecular and Cellular Endocrinology</i> , 2015, 413, 209-216.	3.2	13
20	Characterisation of the adiponectin receptors: The non-conserved N-terminal region of AdipoR2 prevents its expression at the cell-surface. <i>Biochemical and Biophysical Research Communications</i> , 2013, 432, 28-33.	2.1	14